Key result
Cardiac troponin I over 0.020 ng/mL at presentation predicts ~174% higher one-month mortality in ADHF.
Why the study?
Markers predictive of mortality are needed to guide disposition in emergency department patients with ADHF, but Indian data on the prognostic value of Troponin I were lacking.
Does elevated Troponin I at presentation predict one-month mortality in patients with acute decompensated heart failure?
Observational (n=101)
No
Does elevated Troponin I at presentation predict one-month mortality in patients with acute decompensated heart failure?
Elevated cardiac Troponin I at presentation is a significant independent predictor of one-month mortality in patients with acute decompensated heart failure, aiding in emergency department disposition.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for troponin I in acute decompensated heart failure disposition; requires prospective validation before clinical adoption.
BACKGROUND: Acute decompensated heart failure (ADHF) is a highly prevalent diagnosis in the emergency department and is associated with high morbidity and mortality. As mortality remains high even in patients discharged from the emergency, it becomes mandatory to identify markers predictive of mortality in order to guide the disposition of such patients. No literature is available on the prognostic significance of Troponin I in ADHF patients in an emergency setting from an Indian standpoint. OBJECTIVES: This study was aimed at identifying the ability of Troponin I levels at presentation to predict one-month mortality in patients with ADHF. METHODS: The study was conducted in the emergency department of a tertiary healthcare center in north India. Serum cardiac Troponin I (cTnI) levels at presentation were assayed in 101 patients and a one-month follow-up was done. RESULTS: cTnI levels were > 0.02 ng/mL in 51 patients (50.5%). ROC analysis showed an accuracy of 63% in predicting mortality (p < 0.05). Univariate and multivariate analysis showed an OR of 2.58 and 2.74, respectively (p - 0.037 and 0.047, respectively), suggesting cTnI to be a significant predictor of mortality in ADHF. N-terminal proBNP (NT-proBNP) (OR - 2.09; p - 0.229) and left ventricular ejection fraction (OR - 2.01; p - 0.157) were not found to be significant predictors of mortality on regression analysis. CONCLUSION: cTnI levels at presentation are a significant predictor of short-term mortality in ADHF and can be used in an emergency setting to guide treatment, disposition, and follow-up plans of these patients.
No takes yet. Share an insight, caveat, or question.
Sreekumar et al. (2023) conducted an observational in Acute Decompensated Heart Failure (n=101). Cardiac Troponin I (cTnI) > 0.020 ng/mL vs. Cardiac Troponin I (cTnI) ≤ 0.020 ng/mL was evaluated on One-month mortality (OR 2.74, 95% CI 1.01-7.43, p=0.047). Cardiac Troponin I levels > 0.020 ng/mL at presentation significantly predicted one-month mortality in patients with acute decompensated heart failure (adjusted OR 2.74).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: